Nicole Lambert - 08 Dec 2021 Form 4 Insider Report for MYRIAD GENETICS INC (MYGN)

Role: Ms. Lambert's title is Group President, Myriad Oncology, Myriad Women's Health and Myriad International.
Signature: By: Nathan A. Smith For: Nicole Lambert
Issuer symbol: MYGN
Transactions as of: 08 Dec 2021
Net transactions value: $0
Form type: 4
Filing time: 10 Dec 2021, 15:39:47 UTC
Previous filing: 12 Oct 2021
Next filing: 18 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MYGN	Common Stock	Award	$0	+10,000	+6.1%	$0.000000	174,486	08 Dec 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments on January 1, 2023, January 1, 2024, January 1, 2025, and January 1, 2026.
F2	Includes 317 shares of Myriad common stock that were omitted from the reporting person's Form 3, which was amended to reflect such shares on November 1, 2021.

Remarks:

Ms. Lambert's title is Group President, Myriad Oncology, Myriad Women's Health and Myriad International.